This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
by Zacks Equity Research
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
by Zacks Equity Research
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
by Kinjel Shah
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
by Zacks Equity Research
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
by Zacks Equity Research
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
by Zacks Equity Research
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
by Zacks Equity Research
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
by Zacks Equity Research
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
by Zacks Equity Research
PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.
BIIB vs. MYGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BIIB vs. MYGN: Which Stock Is the Better Value Option?
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
Are Investors Undervaluing Biogen (BIIB) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
by Zacks Equity Research
BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
by Zacks Equity Research
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.
Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen (BIIB) delivered earnings and revenue surprises of 8.22% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?